Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
Business Insider

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Seeking Alpha

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
BioWorld

Items Tagged with 'muscarinic M4 receptor positive allosteric modulators'

Dysregulation of cholinergic neurotransmission through muscarinic receptors, particularly the M1 and M4 subtypes, has been implicated in the pathophysiology of schizophrenia. Muscarinic M4 receptor ...
JSTOR Daily

Activation mechanism of the μ-opioid receptor by an allosteric modulator

Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Pharmabiz

Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model

Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model: Geneva, Switzerland Wednesday, April 22, 2026, 18:00 Hrs [IS ...